Company intelligence / Profile preview

Brosh Capital Partners

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Brosh Capital Partners is a Tel Aviv-based investment management firm that operates primarily as an activist hedge fund. The firm specializes in identifying undervalued publicly traded companies, particularly within the Israeli market, and engaging with management to implement strategic changes that unlock shareholder value. While Brosh Capital is not a biotechnology or healthcare company itself, it frequently invests in the life sciences sector and has taken notable activist positions in Israeli biotech firms such as BioLineRx. The firm's investment approach is characterized by deep fundamental analysis and active participation in corporate governance to drive long-term value creation.

Industry: Investors

Beyond the preview

Go deeper on Brosh Capital Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brosh Capital Partners.

Explore the full profile